{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:54:31Z","timestamp":1784202871770,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Up to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited. This study compared Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) and PSMA PET Progression (PPP) criteria in predicting overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). As a secondary aim, PROMISE-based nomograms were assessed as tools for OS prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of 154 BCR PCa patients with baseline and follow-up [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET\/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan\u2013Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41\u20138.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT\u2009+\u2009radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT\u2009+\u2009radiotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07592-6","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:17:14Z","timestamp":1761621434000},"page":"2234-2244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8445-051X","authenticated-orcid":false,"given":"Kaylee","family":"Molin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-6107","authenticated-orcid":false,"given":"Jeremy S. L.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Van Der","family":"Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1351","authenticated-orcid":false,"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-8807","authenticated-orcid":false,"given":"Ghulam Mubashar","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-0719","authenticated-orcid":false,"given":"Martin A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-539X","authenticated-orcid":false,"given":"Jake","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"3","key":"7592_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7592_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/EDBK_351033","volume":"42","author":"NI Simon","year":"2022","unstructured":"Simon NI, et al. Best approaches and updates for prostate cancer biochemical recurrence. Am Soc Clin Oncol Educational Book. 2022;42:352\u20139.","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"7592_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","volume":"44","author":"R Tourinho-Barbosa","year":"2018","unstructured":"Tourinho-Barbosa R, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018;44:14\u201321.","journal-title":"Int Braz J Urol"},{"issue":"12","key":"7592_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7592_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ejca.2006.02.011","volume":"42","author":"L Collette","year":"2006","unstructured":"Collette L, Burzykowski T, Schr\u00f6der FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer. 2006;42(10):1344\u201350.","journal-title":"Eur J Cancer"},{"key":"7592_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, et al. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7592_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics8010016","volume":"8","author":"NP Lenzo","year":"2018","unstructured":"Lenzo NP, Meyrick D, Turner JH. Review of gallium-68 PSMA PET\/CT imaging in the management of prostate cancer. Diagnostics. 2018;8(1):16.","journal-title":"Diagnostics"},{"key":"7592_CR8","doi-asserted-by":"crossref","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. 2020, Soc Nuclear Med. pp. 678\u2013682.","DOI":"10.2967\/jnumed.119.233817"},{"issue":"11","key":"7592_CR9","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"7592_CR10","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","volume":"62","author":"K Michalski","year":"2021","unstructured":"Michalski K, et al. Assessing response to 177Lu-PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med. 2021;62(12):1741\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"7592_CR11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.2967\/jnumed.122.264962","volume":"64","author":"L Lunger","year":"2023","unstructured":"Lunger L, et al. Prognostic role of 68Ga-PSMA11 PET\u2013based response in patients with prostate cancer undergoing taxane-based chemotherapy. J Nucl Med. 2023;64(6):896\u2013901.","journal-title":"J Nucl Med"},{"issue":"12","key":"7592_CR12","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49(12):4271\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7592_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.122.264489","volume":"64","author":"F Kind","year":"2023","unstructured":"Kind F, et al. Prognostic value of tumor volume assessment on PSMA PET after 177Lu-PSMA radioligand therapy evaluated by PSMA PET\/CT consensus statement and RECIP 1.0. J Nucl Med. 2023;64(4):605\u201310.","journal-title":"J Nucl Med"},{"issue":"12","key":"7592_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","volume":"64","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, et al. PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. J Nucl Med. 2023;64(12):1869\u201375.","journal-title":"J Nucl Med"},{"issue":"6","key":"7592_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.123.267234","volume":"65","author":"A Gafita","year":"2024","unstructured":"Gafita A, et al. RECIP 1.0 predicts progression-free survival after [177Lu] Lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65(6):917\u201322.","journal-title":"J Nucl Med"},{"issue":"11","key":"7592_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2967\/jnumed.122.265155","volume":"64","author":"V Murthy","year":"2023","unstructured":"Murthy V, et al. Prognostic value of end-of-treatment PSMA PET\/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis. J Nucl Med. 2023;64(11):1737\u201343.","journal-title":"J Nucl Med"},{"issue":"2","key":"7592_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12149-024-01990-w","volume":"39","author":"QA Shagera","year":"2025","unstructured":"Shagera QA, et al. Evaluating response to radium-223 using 68Ga-PSMA PET\/CT imaging in patients with metastatic castration-resistant prostate cancer. Ann Nucl Med. 2025;39(2):208\u201316.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"7592_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25(9):1188\u2013201.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7592_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed MiTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"4","key":"7592_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ijrobp.2019.03.014","volume":"104","author":"M McCarthy","year":"2019","unstructured":"McCarthy M, et al. A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019;104(4):801\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"7592_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2967\/jnumed.120.258152","volume":"62","author":"RJ Francis","year":"2021","unstructured":"Francis RJ, et al. The australasian radiopharmaceutical trials network: clinical trials, evidence, and opportunity. J Nucl Med. 2021;62(6):755.","journal-title":"J Nucl Med"},{"key":"7592_CR22","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7592_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4274\/mirt.galenos.2021.59254","volume":"30","author":"A Aksu","year":"2021","unstructured":"Aksu A, Kaya G\u00c7. Is SUV corrected for lean body mass superior to SUV of body weight in 68Ga-PSMA PET\/CT? Mol Imaging Radionucl Ther. 2021;30(3):144.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"7592_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0572-z","volume":"9","author":"A Gafita","year":"2019","unstructured":"Gafita A, et al. Evaluation of SUV normalized by lean body mass (SUL) in 68 Ga-PSMA11 PET\/CT: a bi-centric analysis. EJNMMI Res. 2019;9:1\u20136.","journal-title":"EJNMMI Res"},{"issue":"2","key":"7592_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-022-05977-5","volume":"50","author":"GJ Zwezerijnen","year":"2023","unstructured":"Zwezerijnen GJ, et al. Reproducibility of [18F] FDG PET\/CT liver SUV as reference or normalisation factor. Eur J Nucl Med Mol Imaging. 2023;50(2):486\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"40","key":"7592_CR26","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 2019;4(40):1317.","journal-title":"J Open Source Softw"},{"issue":"4","key":"7592_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.123.266702","volume":"65","author":"PE Hartrampf","year":"2024","unstructured":"Hartrampf PE, et al. Prognostic performance of RECIP 1.0 based on [18F] PSMA-1007 PET in prostate cancer patients treated with [177Lu] Lu-PSMA I&T. J Nucl Med. 2024;65(4):560\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"7592_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01211-z","volume":"15","author":"GT Sheikh","year":"2025","unstructured":"Sheikh GT, et al. RECIP 1.0\u2009+\u2009PSA for response assessment in mCRPC patients treated with 225Ac\/177Lu PSMA combination therapy. EJNMMI Res. 2025;15(1):19.","journal-title":"EJNMMI Res"},{"issue":"9","key":"7592_CR29","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.7150\/thno.96738","volume":"14","author":"AT K\u00fcper","year":"2024","unstructured":"K\u00fcper AT, et al. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: is there value beyond localization of disease? Theranostics. 2024;14(9):3623.","journal-title":"Theranostics"},{"key":"7592_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.12.027","author":"FA Mourato","year":"2025","unstructured":"Mourato FA, et al. Prognostic value of response evaluation using PSMA PET\/CT in patients with metastatic prostate cancer (RECIP 1.0): a systematic review and meta-analysis. Acad Radiol. 2025. https:\/\/doi.org\/10.1016\/j.acra.2024.12.027.","journal-title":"Acad Radiol"},{"issue":"13","key":"7592_CR31","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","volume":"50","author":"J Kendrick","year":"2023","unstructured":"Kendrick J, et al. Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga] Ga-PSMA-11 PET images. Eur J Nucl Med Mol Imaging. 2023;50(13):4077\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7592_CR32","volume":"4","author":"H Maeda","year":"2021","unstructured":"Maeda H, et al. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Rep. 2021;4(3):e1334.","journal-title":"Cancer Rep"},{"issue":"4","key":"7592_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200195","volume":"2","author":"LA Gharzai","year":"2023","unstructured":"Gharzai LA, et al. Meta-analysis of candidate surrogate end points in advanced prostate cancer. NEJM Evid. 2023;2(4):EVIDoa2200195.","journal-title":"NEJM Evid"},{"key":"7592_CR34","doi-asserted-by":"publisher","first-page":"110869","DOI":"10.1016\/j.radonc.2025.110869","volume":"207","author":"M Hotta","year":"2025","unstructured":"Hotta M, et al. Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study. Radiother Oncol. 2025;207:110869.","journal-title":"Radiother Oncol"},{"issue":"1","key":"7592_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7592_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01229-3","volume":"15","author":"S Yadav","year":"2025","unstructured":"Yadav S, et al. Pre-or post-chemotherapy: effect on PSMA uptake. EJNMMI Res. 2025;15(1):36.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07592-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07592-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07592-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:50Z","timestamp":1771479530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07592-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7592"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07592-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was granted by the Human Research Ethics Committee of Sir Charles Gairdner Hospital (RGS1736).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable \u2013 images are fully de-identified radiological data and no individual consent for publication was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}